deflazacort 22.75 MG/mL Oral Suspension

RxCUI: 1870964
RxNorm name: deflazacort 22.75 MG/mL Oral Suspension
Display name: deflazacort 22.75 MG/mL Oral Suspension
Full name: deflazacort 22.75 MG/mL Oral Suspension
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:52

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 8 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Deflazacort Oral Suspension	DEFLAZACORT	Doppel Farmaceutici S.r.l.	40a833a4-e029-a99e-e063-6394a90afd50	2026-07-29	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
Deflazacort Oral Suspension	DEFLAZACORT	Zydus Pharmaceuticals (USA) Inc.	14569f71-573e-49fd-b80e-b3b52531b1c8	2026-07-23	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
JAYTHARI Oral Suspension	DEFLAZACORT	Zydus Pharmaceuticals (USA) Inc.	abf1dba1-cfd8-4a05-aa2b-ffacfbeb9fa9	2026-07-23	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
KYMBEE	DEFLAZACORT	Upsher-Smith Laboratories, LLC	ba749cfb-813d-4799-9e7b-44ede92065f2	2026-06-18	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
Deflazacort Oral Suspension	DEFLAZACORT ORAL	Cranbury Pharmaceuticals, LLC	881785a5-41b4-4679-a29b-5d77ca51ca60	2026-06-03	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
Deflazacort Oral Suspension	DEFLAZACORT ORAL	Sun Pharmaceutical Industries, Inc.	2fac1332-0247-1047-e063-6294a90a557f	2026-01-27	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
EMFLAZA	DEFLAZACORT	PTC Therapeutics, Inc.	31b347d2-f156-4055-9d8f-7cf0df420296	2025-11-13	Warnings, Adverse reactions	Exact identifier rxcui: 1870964
PYQUVI	DEFLAZACORT	Aucta Pharmaceuticals, Inc.	39854f19-d8be-6438-e063-6394a90a9422	2025-07-09	Warnings, Adverse reactions	Exact identifier rxcui: 1870964

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 7 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
31b347d2-f156-4055-9d8f-7cf0df420296	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	21	These highlights do not include all the information needed to use EMFLAZA ® safely and effectively. See full prescribing information for EMFLAZA. EMFLAZA ® (deflazacort) tablets, for oral use EMFLAZA ® (deflazacort) oral suspension Initial U.S. Approval: 2017	20251113
881785a5-41b4-4679-a29b-5d77ca51ca60	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	8	These highlights do not include all the information needed to use DEFLAZACORT ORAL SUSPENSION safely and effectively. See full prescribing information for DEFLAZACORT ORAL SUSPENSION. DEFLAZACORT oral suspension Initial U.S. Approval: 2017 Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.	20250531
2fac1332-0247-1047-e063-6294a90a557f	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	2	These highlights do not include all the information needed to use DEFLAZACORT ORAL SUSPENSION safely and effectively. See full prescribing information for DEFLAZACORT ORAL SUSPENSION. DEFLAZACORT oral suspension Initial U.S. Approval: 2017 Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.	20260127
14569f71-573e-49fd-b80e-b3b52531b1c8	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	2	These highlights do not include all the information needed to use DEFLAZACORT ORAL SUSPENSION safely and effectively. See full prescribing information for DEFLAZACORT ORAL SUSPENSION. DEFLAZACORT oral suspension Initial U.S. Approval: 2017	20251127
abf1dba1-cfd8-4a05-aa2b-ffacfbeb9fa9	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	1	These highlights do not include all the information needed to use JAYTHARI safely and effectively. See full prescribing information for JAYTHARI . JAYTHARI (deflazacort) oral suspension Initial U.S. Approval: 2017	20251114
40a833a4-e029-a99e-e063-6394a90afd50	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	1	These highlights do not include all the information needed to use DEFLAZACORT ORAL SUSPENSION safely and effectively. See full prescribing information for DEFLAZACORT ORAL SUSPENSION. DEFLAZACORT oral suspension Initial U.S. Approval: 2017	20251014
39854f19-d8be-6438-e063-6394a90a9422	deflazacort 22.75 MG/mL Oral Suspension [PSN] · deflazacort 22.75 MG/ML Oral Suspension [SCD]	2	1	These highlights do not include all the information needed to use PYQUVI safely and effectively. See full prescribing information for PYQUVI. PYQUVI TM (deflazacort) oral suspension Initial U.S. Approval: 2017	20250709